With total potential shares of 700m, $4 a share wo
Post# of 153778
(Total Views: 365)
Posted On: 05/25/2019 6:08:32 PM
Re: LaundryMoney #3470
With total potential shares of 700m, $4 a share would be 2.8b market cap.
When I do DD I figure 5x projected revenue as the share price value. I initially came up with 500m 1st year sales and 980m 2nd year with combo in U.S. That was based on a 35k price tag for the drug, which is what I believe insurance companies would be more likely to pay.
If NP does go through with a 120k price tag I would think 350m/900m is more realistic given that there will be much higher pushback on insurance pre-approval.
So 2020 should be $1.75b, 2021 - 4.5b. This is if we outsource sales (and capture 60% of revenue) rather than sell off the HIV indication.
Those numbers completely disregard the pipeline.
CYDY is the red-headed stepchild of the biopharma world. We're given very little credit for what we do have, even with FDA approval imminent.
The milestones that will change that are FDA approval and good script numbers. With those in place then TNBC and other indications will be taken seriously.
Best estimate NASDAQ listing 3Q 2020, $4 share, 4Q 2020.
When I do DD I figure 5x projected revenue as the share price value. I initially came up with 500m 1st year sales and 980m 2nd year with combo in U.S. That was based on a 35k price tag for the drug, which is what I believe insurance companies would be more likely to pay.
If NP does go through with a 120k price tag I would think 350m/900m is more realistic given that there will be much higher pushback on insurance pre-approval.
So 2020 should be $1.75b, 2021 - 4.5b. This is if we outsource sales (and capture 60% of revenue) rather than sell off the HIV indication.
Those numbers completely disregard the pipeline.
CYDY is the red-headed stepchild of the biopharma world. We're given very little credit for what we do have, even with FDA approval imminent.
The milestones that will change that are FDA approval and good script numbers. With those in place then TNBC and other indications will be taken seriously.
Best estimate NASDAQ listing 3Q 2020, $4 share, 4Q 2020.
(0)
(0)